Durham pharma takes $300M loan to pay down debt


A Durham pharmaceutical company has secured a $450 million financing agreement to help reduce its dependence on capital markets.

Previous Facing a million square feet of vacant space, Tower Square adds spec suites
Next Truist Financial reports a mixed bag for Q1, missing analysts' target for earnings